Cytomegalovirus immunoglobulin, human

Thông tin thuốc gốc
Chỉ định và Liều dùng
Prophylaxis of cytomegalovirus infection in organ transplantation
Adult: For kidney transplant recipients: Initially, 150 mg/kg given within 72 hours of transplantation, followed by 100 mg/kg once every 2 weeks for 4 doses (2-,4-,6- and 8 weeks post-transplant), then 50 mg/kg once every 4 weeks for 2 doses (12- and 16 weeks post-transplant), thereafter. For heart, liver, lung, and pancreas transplant recipients: Initially, 150 mg/kg given within 72 hours of transplantation, then once every 2 weeks for 4 more doses (2-,4-,6- and 8 weeks post-transplant), followed by 100 mg/kg every 4 weeks for 2 doses (12- and 16 weeks post-transplant), thereafter. All doses are given via IV infusion at a rate of 15 mg/kg/hour, may be increased gradually according to patient safety. Max rate: 60 mg/kg/hour. In case of organ transplants from CMV seropositive donors to CMV seronegative recipients, concomitant use with ganciclovir may be considered. Dosing information may vary among countries, refer to specific product guideline or local guidelines.
Chống chỉ định
Hypersensitivity. Selective immunoglobulin A (IgA) deficiency.
Thận trọng
Patient with predisposing factors to acute renal failure (e.g. sepsis, paraproteinaemia, diabetes mellitus, volume depletion, receiving nephrotoxic drugs), pre-existing factors for thrombotic events (e.g. hypertension, advanced age, history of vascular disease or thrombotic episodes, known or suspected hyperviscosity, impaired cardiac output, prolonged periods of immobilisation, severe hypovolaemia, acquired or inherited thrombophilic disorders). Obese patient. Patient naive to human Ig, switched from another human Ig product, or who had a long infusion interval since the previous one. Renal impairment. Pregnancy.
Phản ứng phụ
Significant: Hypersensitivity/anaphylactic reactions with hypotension; haemolytic anaemia, transfusion related acute lung injury (acute noncardiogenic pulmonary oedema), thromboembolic events (e.g. MI, stroke, DVT, pulmonary embolism), decreased neutrophil and/or neutropenia. Rarely, aseptic meningitis syndrome (high doses), acute renal impairment (including acute renal failure, increased serum creatinine, oliguria, osmotic nephrosis), haemolysis.
Gastrointestinal disorders: Nausea, vomiting.
General disorders and administration site conditions: Chills, fatigue, pyrexia.
Investigations: Increased BUN.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain, muscle cramps.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Wheezing.
Skin and subcutaneous tissue disorders: Rash, pruritus, drug eruption, erythema.
Vascular disorders: Flushing.
IV/Parenteral: C
Assess for volume depletion prior to therapy. Monitor urine output; renal function (e.g. BUN, serum creatinine prior to initiation and periodically thereafter); vital signs including blood pressure (during infusion); blood viscosity at baseline (in at-risk patients). Check for the presence of antineutrophil antibodies (if clinically indicated). Assess for signs and symptoms of anaphylactic reactions, infusion-related reactions (during and after infusion), and haemolytic anaemia.
Tương tác
May diminish the therapeutic effect of live vaccines (e.g. measles, mumps, rubella, varicella vaccines).
Lab Interference
May cause false-positive results in serological tests (e.g. direct Coombs test).
Tác dụng
Description: Cytomegalovirus immunoglobulin is an immunoglobulin G (IgG) preparation that contains a high concentration of antibodies directed against cytomegalovirus (CMV). It raises the relevant antibodies to a level that is sufficient to attenuate or decrease the incidence of serious CMV disease in case of exposure.
Distribution: Rapidly distributed between plasma and extravascular fluid. Crosses the placenta and enters breastmilk.
Excretion: Elimination half-life: 8-24 days.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Phân loại ATC
J06BB09 - cytomegalovirus immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Anon. Cytomegalovirus Immune Globulin (Intravenous-Human). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 30/06/2020.

Anon. Cytomegalovirus Immune Globulin IV. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 30/06/2020.

Buckingham R (ed). Cytomegalovirus Immunoglobulins. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 30/06/2020.

Cytogam (CSL Behring AG). DailyMed. Source: U.S. National Library of Medicine. Accessed 30/06/2020.

Cytotect CP Biotest 100 U/mL Solution for Infusion (Biotest Pharma GmbH). MHRA. Accessed 30/06/2020.

Joint Formulary Committee. Cytomegalovirus Immunoglobulin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 30/06/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Cytomegalovirus immunoglobulin, human từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Cytotect CP
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in